FDA sent O.N. Diagnostics a warning letter dated September 1, 2026, following a March 12 to 17 inspection, over VirtuOst VFA version 3.0.0, an update to the company's vertebral fracture assessment software for spine CT images originally cleared in 2017 under 510(k) K171435. FDA found the updated software adulterated under section 501(f)(1)(B) and misbranded under section 502(o) of the Federal Food, Drug, and Cosmetic Act for shipping without a new 510(k) clearance.
Version 3.0.0 made three changes FDA said each independently required a new premarket submission. It added a new machine learning model for vertebral landmarking, which FDA said "fundamentally changes how the device performs, fails, and affects patients." It moved the software from a desktop application to a web based architecture. And it migrated the underlying technology platform, which required re-verification and re-validation of the entire codebase, including third party libraries FDA said it had never reviewed against a Software Bill of Materials.
The cybersecurity finding sits in the second change. FDA cited "network-exposed attack surfaces, authentication vulnerabilities" and other risks that come with moving a desktop application onto an internet accessible platform, and the agency's letter notes that O.N. Diagnostics itself acknowledged the move expanded its "cyberattack surface area" during the inspection.
FDA asked the company to stop distributing version 3.0.0 until it resolves the issues, and it separately cited Quality Management System Regulation violations, including corrective action and supplier controls, and Medical Device Reporting violations. A company spokesperson told AuntMinnie that O.N. Diagnostics is validating a revised version that removes the cited machine learning feature and adds updated cybersecurity controls and documentation, and that VirtuOst VFA remains available through the company's existing in-house clinical service.
This is one of the clearer examples yet of FDA treating an architecture change, not only an algorithm change, as cybersecurity grounds for a new submission. A desktop to cloud migration is now explicitly a 524B question, not just a 807.81(a)(3) question about the software itself.
The letter arrives as FDA separately pushes manufacturers to document SBOMs and third party component changes under its February 2026 premarket cybersecurity guidance, so a company planning any similar move from local to hosted delivery should expect FDA to ask for updated threat modeling, risk assessment, and penetration testing alongside the usual algorithm validation evidence.